Artemis One Health
VALORIZATION Projects, RABIES
Rabies virus (RABV), a member of the Lyssavirus genus is transmitted by the bite or scratches of infected animals (primarily dogs but also by cats, wildlife and bats), causes rabies encephalitis and accounts for more than 55,000 reported fatal human cases each year. In the absence of pre-existing immunity (through vaccination) or prompt post-exposure prophylaxis (PEP) RABV infection almost invariably leads to lethal encephalitis: only five documented cases of survival of clinical rabies cases in humans have been reported to date. This makes rabies an infectious disease with one of the highest mortality rates known to man.
Due to its prevalence predominantly in developing countries, rabies can be classified as a Neglected Tropical Disease. Innovation in the field of Neglected Tropical Diseases is not self-evident due to the limited return on investment on the high development costs. To improve the chances that the results of the Asklepios consortium will be further developed, Artemis is engaged in a number of studies and activities to elucidate and improve the business case for innovation in human rabies medication. One of these studies identified the innovation barriers for developing and introducing new medical treatment. Insight in the innovation barriers enables the stakeholders working in the field of rabies to effectively tackle these barriers and allows for faster and more efficient development of such compounds in the future.
ASKLEPIOS (602825) is an innovation research project funded by the EU FP7 program HEALTH.2013.2.3.4-1 – Neglected infectious disease of Central and Eastern Europe FP7-HEALTH-2013-INNOVATION-1.